Trial · NCT04470297
Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19
NCT04470297, Phase 2, Unknown, Associação Fundo de Incentivo à Pesquisa
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19. Trials, record NCT04470297. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04470297
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19
- NCT number
- NCT04470297
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Associação Fundo de Incentivo à Pesquisa
- Conditions
- Covid19, Lung Injury
- Interventions
- Ramelteon 8mg
- First posted
- 2020-07-14
- Last updated
- 2020-07-24
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to resolution of symptoms [National Early Warning Score 2 (NEWS2) of 0] | enrollment is day 0 | Defined as a National Early Warning Score 2 (NEWS2) of 0 maintained for 24 hours \[Time Frame: Assessed daily (enrollment is day 0)\] The NEWS consists of a simple aggregate scoring system based on physiological measurements, regularly registered in inpatient settings, including six parameters: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, and temperature. |
| Secondary | Clinical worsening to critical COVID-19 illness | until Day 30 | Critical COVID-19 illness as a composite of admission to the intensive care unit (ICU), invasive ventilation, or death |
| Secondary | Duration of supplemental oxygen therapy | until day 14 | Measured by duration of use of supplemental oxygen (if applicable) |
| Secondary | Duration of mechanical ventilation (if applicable) | until day 30 | Measured by duration of use of mechanical ventilation |
| Secondary | Duration of hospitalisation | until day 30 | Measured by duration of hospitalization |
| Secondary | Proportion of participants with virologic clearance in nasopharyngeal swab RT-PCR | Day 14 | Presence or absence of SARS-CoV-2 Viral RNA in nasopharyngeal swab or lower respiratory secretions |
| Secondary | C-reactive protein (CRP) level's reduction | Days 3, 5 and 8 | Reduction of C-reactive protein levels \> 50% in comparison with PCR levels at the admission |
| Secondary | Incidence of New Onset Lymphopenia | Through study completion, average of 15 days | Incidence of new onset lymphopenia during hospitalization measured by blood draw |
| Secondary | Direct bilirubin level's reduction | Measured in study Days 3, 5, and 8 | Reduction of mean direct bilirubin levels in comparison with levels at the admission |
| Secondary | Side Effects | until day 14 | Differences in number of patients in study arms who experienced side effects |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04470297
GET https://conductscience.org/api/trials/v1/NCT04470297/registered